Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers.
JAMA
; 280(2): 157-8, 1998 Jul 08.
Article
em En
| MEDLINE
| ID: mdl-9669789
ABSTRACT
Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and beta-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and beta-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Choque Cardiogênico
/
Tetra-Hidronaftalenos
/
Benzimidazóis
/
Di-Hidropiridinas
/
Bloqueadores dos Canais de Cálcio
/
Antagonistas Adrenérgicos beta
Limite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
JAMA
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos